Literature DB >> 11865418

Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana.

Sébastien P Gagneux1, Abraham Hodgson, Tom A Smith, Thierry Wirth, Ingrid Ehrhard, Giovanna Morelli, Blaise Genton, Fred N Binka, Mark Achtman, Gerd Pluschke.   

Abstract

After an epidemic of serogroup A meningococcal meningitis in northern Ghana, a gradual disappearance of the epidemic strain was observed in a series of five 6-month carriage surveys of 37 randomly selected households. As serogroup A Neisseria meningitidis carriage decreased, an epidemic of serogroup X meningococcal carriage occurred, which reached 18% (53/298) of the people sampled during the dry season of 2000, coinciding with an outbreak of serogroup X disease. These carriage patterns were unrelated to that of Neisseria lactamica. Multilocus sequence typing and pulsed-field gel electrophoresis of the serogroup X bacteria revealed strong similarity with other strains isolated in Africa during recent decades. Three closely related clusters with distinct patterns of spread were identified among the Ghanian isolates, and further microevolution occurred after they arrived in the district. The occurrence of serogroup X outbreaks argues for the inclusion of this serogroup into a multivalent conjugate vaccine against N. meningitidis.

Entities:  

Mesh:

Year:  2002        PMID: 11865418     DOI: 10.1086/339010

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Genetic basis for biosynthesis of the (alpha 1-->4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X.

Authors:  Yih-Ling Tzeng; Corie Noble; David S Stephens
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z.

Authors:  Désirée E Bennett; Robert M Mulhall; Mary T Cafferkey
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Neisseria meningitidis serogroup X sequence type 767 in Turkey.

Authors:  Abdullah Kiliç; Orhan Bedir; A Celal Basustaoglu; Holly B Bratcher; Keith A Jolley; Gurkan Mert
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

Review 4.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

5.  Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008.

Authors:  Mignon du Plessis; Chivonne Moodley; Kedibone M Mothibeli; Azola Fali; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

6.  The changing face of meningococcal disease in West Africa.

Authors:  B Greenwood
Journal:  Epidemiol Infect       Date:  2007-07       Impact factor: 2.451

Review 7.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

8.  Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes.

Authors:  Pierre Nicolas; Gunnstein Norheim; Eric Garnotel; Saacou Djibo; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

9.  Clonal groupings in serogroup X Neisseria meningitidis.

Authors:  Sébastien Gagneux; Thierry Wirth; Abraham Hodgson; Ingrid Ehrhard; Giovanna Morelli; Paula Kriz; Blaise Genton; Tom Smith; Fred Binka; Gerd Pluschke; Mark Achtman
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

10.  Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003.

Authors:  Judith E Mueller; Lassana Sangaré; Berthe-Marie Njanpop-Lafourcade; Zekiba Tarnagda; Yves Traoré; Seydou Yaro; Raymond Borrow; Bradford D Gessner; Pierre Nicolas
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.